RhumbLine Advisers’s Avalo Therapeutics AVTX Stock Holding History

RhumbLine Advisers’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-17	Closed	-$36K	–	3104
2022 Q1	$36K	Buy	17 +1	+6%	+$2.51K	﹤0.01%	2990
2021 Q4	$80K	Hold	16	–	–	﹤0.01%	2960
2021 Q3	$103K	Hold	16	–	–	﹤0.01%	2992
2021 Q2	$151K	Buy	16 +7	+78%	+$58.6K	﹤0.01%	2944
2021 Q1	$77K	Hold	9	–	–	﹤0.01%	2957
2020 Q4	$66K	Buy	9 +2	+29%	+$13.9K	﹤0.01%	3005
2020 Q3	$49K	Sell	7 -1	-13%	-$7.52K	﹤0.01%	2950
2020 Q2	$60K	Buy	8 +2	+33%	+$14.5K	﹤0.01%	3020
2020 Q1	$43K	Hold	6	–	–	﹤0.01%	2872
2019 Q4	$94K	Hold	6	–	–	﹤0.01%	2877
2019 Q3	$57K	Hold	6	–	–	﹤0.01%	2919
2019 Q2	$94K	Buy	+6	New	+$90.9K	﹤0.01%	2934

Other funds holding AVTX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RhumbLine Advisers's AVTX Position: Q2 2022 in Review

RhumbLine Advisers sold out of Avalo Therapeutics (AVTX) in Q2 2022, closing a stake of 17 shares — an estimated $36K sold.

RhumbLine Advisers first reported a position in AVTX in Q2 2019 and held it in 12 quarters. The position peaked at $151K in Q2 2021. 43 funds tracked by Wall St. Rank hold AVTX as of Q2 2022.

RhumbLine Advisers reported no remaining Avalo Therapeutics position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 17 Avalo Therapeutics shares in Q2 2022, an estimated $36K.
RhumbLine Advisers first reported a position in Avalo Therapeutics in Q2 2019 and held it in 12 quarters.
RhumbLine Advisers's Avalo Therapeutics position peaked at $151K in Q2 2021.
43 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.